Patients with non-Hodgkin lymphomas (NHLs) resistant to standard therapies have a dismal prognosis. The work cannot be changed in any way or used commercially without permission from the journal. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited.
TCEL BCELL TRIAL
GH, UJ, and NW participated in the Novartis JULIET trial and the writing of the paper.
NW has received honoraria from AOP Orphan, Jazz, Novartis, Therakos Mallinckrodt Pharmaceuticals, Sanofi Genzyme, and received research funding from Therakos Mallinckrodt Pharmaceuticals, and Sanofi Genzyme.ĭisclosure: The authors have indicated they have no potential conflicts of interest to disclose. UJ has received honoraria from AbbVie, Amgen, AOP Orphan, Celgene, Emergent, Gilead, GlaxoSmithKline, Janssen, Mundipharma, Novartis, Roche, and received research funding from Celgene, Emergent, Gilead, Infinity, Janssen, Mundipharma, Novartis, Roche, Takeda-Millennium, and TrueNorth Therapeutics. HemaSphere, 2019 00:00.įunding/support: GH has received honoraria from Celgene, Gilead, GlaxoSmithKline, Janssen, Novartis, Roche, Takeda, and received research funding from Gilead. CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope. e-mail: ).Ĭitation: Hopfinger G, Jäger U, Worel N. 1Department of Internal Medicine I, Bone Marrow Transplantation Unit, Medical University of Vienna, Vienna, AustriaĢDepartment of Internal Medicine I, Division of Hematology and Hemostaseology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, AustriaģDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, AustriaĬorrespondence: Nina Worel (.
0 kommentar(er)
